Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2‐negative metastatic breast cancer.

MLA

Jeong, Hyehyun, et al. “Final Results of the Randomized Phase 2 LEO Trial and Bone Protective Effects of Everolimus for Premenopausal Hormone Receptor‐positive, HER2‐negative Metastatic Breast Cancer.” International Journal of Cancer, vol. 149, no. 4, Aug. 2021, pp. 917–24. EBSCOhost, https://doi.org/10.1002/ijc.33613.

APA

Jeong, H., Jeong, J. H., Kim, J. E., Ahn, J., Jung, K. H., Koh, S., Cheon, J., Sohn, J., Kim, G. M., Lee, K. S., Sim, S. H., Park, I. H., & Kim, S. (2021). Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2‐negative metastatic breast cancer. International Journal of Cancer, 149(4), 917–924. https://doi.org/10.1002/ijc.33613

Chicago

Jeong, Hyehyun, Jae Ho Jeong, Jeong Eun Kim, Jin‐Hee Ahn, Kyung Hae Jung, Su‐Jin Koh, Jaekyung Cheon, et al. 2021. “Final Results of the Randomized Phase 2 LEO Trial and Bone Protective Effects of Everolimus for Premenopausal Hormone Receptor‐positive, HER2‐negative Metastatic Breast Cancer.” International Journal of Cancer 149 (4): 917–24. doi:10.1002/ijc.33613.